<DOC>
	<DOC>NCT02620306</DOC>
	<brief_summary>The purpose of this study is to evaluate the Efficacy and Safety of Fimasartan in patients with hypertensive diabetic chronic kidney disease.</brief_summary>
	<brief_title>A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan</brief_title>
	<detailed_description>The randomized subjects will take the investigational product (Fimasartan or Losartan) corresponding to each treatment group for 24 weeks. After that, all subjects will take Fimasartan for additional 120 weeks in an open-label, 2-parallel group study conducted with 2 groups in accordance with the blood pressure control criteria.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>1. Male and female adults aged 19 to 70 years 2. Blood pressure: Mean blood pressure is as below at screening. For treatmentnaïve patients: 140 mmHg ≤ SBP &lt; 180 mmHg and DBP &lt; 110 mmHg For patients who are taking ACEI or ARB: 130 mmHg ≤ SBP &lt; 180 mmHg and DBP &lt; 110 mmHg 3. eGFR: ≥ 30 ml/min/1.73 m2 within the past 6 months 4. Albuminuria (ACR) excretion volume of ≥ 300 mg/g (or mg/day) within the past 6 months 5. Patients with diabetes 6. Voluntarily provided a written consent to participate 7. Able to understand this study, be cooperative in the execution of the study 1. Severe hypertension with mean SBP ≥ 180 mmHg or DBP ≥ 110 mmHg 2. Orthostatic hypotension with symptoms 3. Insulin dependent diabetes mellitus or uncontrolled diabetes mellitus 4. Patients on dialysis, patients with clinically significant cardiac and hepatic diseases</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>